CTOs on the Move

Genoa Pharmaceuticals Inc

www.genoapharma.com

 
Genoa is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (Aerodone™) for the treatment of IPF. With offices in Seattle and San Diego, Genoa`s experienced clinical and inhaled product development team is rapidly advancing Aerodone for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Genoa Pharmaceuticals Inc raised $62M on 05/15/2017

Similar Companies

Biocheck

Biocheck is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Integrated Biomolecule Corporation

Integrated Biomolecule Corporation is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Benitec Ltd

Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration.

Paragon Biosciences

Paragon Biosciences invests in and launches biopharmaceutical companies to develop novel therapies for severe medical conditions which do not yet have adequate treatments. Our mission is to help people live longer, healthier lives. Paragon advances that mission through its contribution of Bioscience Innovation Capital(TM): For rare and complex diseases, Paragon analyzes the viability of potential therapies, invests in new biopharmaceutical companies to further develop promising treatments, catalyzes the progress of its portfolio companies through early-incubation services, and provides clinical and regulatory guidance by a team with a near-perfect track record of first-cycle novel drug approvals.

Zealand Pharma

Changing lives with next generation peptide therapeutics